Abstract
BackgroundFor individuals with ovarian cancer (OC), therapy options mainly depend on BRCA1/2 germline status. What is the prevalence of deleterious somatic variants, that is, does genetic tumour testing identify subgroups...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have